Rabacfosadine

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Rabacfosadine

CAS No. : 859209-74-8

MCE 国际站：Rabacfosadine

产品活性：Rabacfosadine (GS-9219) 是核苷类似物 PMEG 的新型前药，用作优先靶向淋巴细胞的细胞毒性剂。

研究领域：Cell Cycle/DNA Damage

作用靶点：Nucleoside Antimetabolite/Analog

In Vitro: In lymphocytes, Rabacfosadine (GS-9219) is converted to its active metabolite, 9-(2-phosphonylmethoxyethyl)guanine (PMEG) diphosphate, via enzymatic hydrolysis, deamination, and phosphorylation. GS-9219 has substantial antiproliferative activity against activated lymphocytes and hematopoietic tumor cell lines. The ability of Rabacfosadine to inhibit the proliferation of activated lymphocytes and of tumor cells of hematopoietic origin is investigated. Rabacfosadine inhibits the proliferation of mitogen-stimulated T and B lymphocytes with EC₅₀ values of 135 and 42 nM, respectively, as determined by BrdUrd incorporation. To compare the activity of GS-9219 in dividing and nondividing cells, Rabacfosadine is evaluated in these populations using a metabolism-based sodium XTT assay instead of BrdUrd assays. Results from the XTT assay shows a 127-fold difference between the EC₅₀ values of Rabacfosadine in quiescent (EC₅₀=17.2 μM) and proliferating (EC₅₀=135 nM) cells. These results indicate a substantial selectivity of Rabacfosadine toward actively replicating lymphoblasts.

In Vivo: Rabacfosadine (RAB) has substantial single-agent activity in dogs with lymphoma, and a different mechanism of action than Doxorubicin (DOX). Open-label, multicenter prospective clinical trial. Dogs receive alternating Rabacfosadine (1.0 mg/kg IV weeks 0, 6, 12) and Doxorubicin (30 mg/m² IV weeks 3, 9, 15). Dogs that achieved complete response (CR) are followed by monthly evaluations. Complete clinicopathological evaluation and assessment of remission and adverse event (AEs) are performed every 21 days. Acute AEs, occurring within 21 days after administration of the first dose of each agent, are compared between Rabacfosadine and Doxorubicin in 46 dogs receiving at least 1 dose of each agent.

相关产品：5-Fluorouracil | Gemcitabine | Decitabine | 5-Azacytidine | 5-BrdU | Cytarabine | Fludarabine | Capecitabine | Adenosine | Ganciclovir | 6-Mercaptopurine | Floxuridine | Dacarbazine | Forodesine hydrochloride | 8-Azaguanine | Carmofur | Stavudine | Trifluridine/tipiracil hydrochloride mixture | Raltitrexed | Clofarabine | Nelarabine | Tegafur | Cytidine

热门产品线：重组蛋白 | 化合物库 | 天然产物 | 染料试剂 | PROTAC | 同位素标记物 | 寡核苷酸

Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds | Oligonucleotides

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪前沿的制药及生命科学研究进展，为您提供全球前沿的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。